Cadonilimab
As of the edition of 20 October 2026, Cadonilimab is an antibody: in active development; acts on CTLA4 and PDCD1.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Active, 2026
- Kind
- Antibody
- Registered trials
- 191, 6 stopped early
- Disease areas
- Cancer; Digestive system; Pregnancy and women's health; Urinary and reproductive; Lungs and airways; Skin and connective tissue
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
1 company-target row on route B because of this drug.
Companies on route B for this drug
In the product1 company-target row is on route B because of Cadonilimab.
See the 1 company-target row on route B for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 9 | 0 | 8 | 0 |
| Phase 1 | 13 | 4 | 6 | 0 |
| Phase 2 | 152 | 17 | 85 | 6 |
| Phase 3 | 17 | 1 | 16 | 0 |
| All trials | 191 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Akesobio | Lead sponsor of trials | 2017 to now |
| Akeso | Lead sponsor of trials | 2019 to now |
| Shanghai Pharmaceuticals | Lead sponsor of trials | 2023 to now |
| RemeGen | Lead sponsor of trials | 2024 to now |